NeuroClues Raises €10M for Brain Health Diagnostic Tech

NeuroClues, a Franco-Belgian medtech innovator, has successfully closed a €10 million Series A funding round to accelerate the global rollout of its groundbreaking diagnostic technology. The investment, spearheaded by Teampact Ventures, a fund backed by prominent athletes including Raphaël Varane and Nikola Karabatic, signals strong confidence in the company's potential to revolutionize early detection of neurodegenerative diseases.

The funding round also saw significant participation from White Fund, a Belgian firm specializing in medical technology, and the European Innovation Council (EIC) Fund. Existing investors, namely Invest BW, Leansquare, and Wallonie Entreprendre, also contributed, underscoring their continued belief in NeuroClues' vision. This latest infusion of capital follows a €5 million round completed in April 2024, highlighting the company's rapid progress.

Founded in 2020 by Antoine Pouppez, a former executive at cancer diagnostics firm IBA, alongside researchers Pierre Daye and Pierre Pouget from the Brain Institute, NeuroClues has developed a non-invasive system that analyzes eye movements to identify early markers of neurological conditions. The technology, often described as a 'brain stethoscope,' utilizes a headset to capture high-frequency infrared images of eye motion as patients track a moving point on a screen. This analysis, completed in minutes, can detect subtle biomarkers indicative of diseases like Parkinson's, Alzheimer's, and multiple sclerosis years before clinical symptoms manifest.

With the CE marking secured in January 2025, NeuroClues has already deployed approximately thirty devices across leading European institutions, including university hospitals, private neurology practices, and research centers in France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the United Kingdom. The company is actively engaged in research collaborations, such as the 'Iceberg' project with the Brain Institute, to further refine its predictive capabilities for Parkinson's disease progression.

The substantial Series A funding will be instrumental in scaling commercial operations across Europe and preparing for market entry into the United States. NeuroClues is actively expanding its team in France and finalizing distribution agreements within the EMEA region. To foster broader engagement, the company is also offering a limited €1.5 million tranche of the round to individual investors via LITA.

“This Series A round validates our technology and our execution capabilities,” stated Antoine Pouppez, CEO of NeuroClues. “We achieved CE certification in five months, initiated commercial deployments swiftly, and are building a normative database with 25,000 participants. As our dataset grows, our solution will offer unprecedented accuracy and speed in identifying specific pathologies.” The implications are profound, given that neurodegenerative diseases affect one in three individuals and are notoriously difficult to diagnose early. Projections indicate that the global number of Parkinson's patients could double to 13 million by 2040, underscoring the critical need for advanced diagnostic tools like NeuroClues'.